دورة المؤشرنت للتحليل الفني
50 دينار كويتي
أنت تستخدم أحد المتصفحات القديمة. قد لا يتم عرض هذا الموقع أو المواقع الأخرى بشكل صحيح.
يجب عليك ترقية متصفحك أو استخدام أحد المتصفحات البديلة.
يجب عليك ترقية متصفحك أو استخدام أحد المتصفحات البديلة.
Lftc.ob
- بادئ الموضوع بو راشد2
- تاريخ البدء
ممدوح
عضو محترف
- التسجيل
- 24 أغسطس 2002
- المشاركات
- 1,140
سهم طبي حلو وهدفه فوق كما آمل ان شاء الله
وعليه هذا الخبر الحليوة
TC Lifestream Technologies` Advertising and Promotion Programs Kick In; Lifestream Sees Expansion in 2005 as Advertising and Targeted Marketing Increase Sales 29%
July 13, 2004 06:30:00 (ET)
POST FALLS, Idaho, Jul 13, 2004 (BUSINESS WIRE) -- Lifestream Technologies, Inc. (LFTC, Trade), the leading manufacturer of home cholesterol monitors and professional screening devices, today announced that sales within a subset of its primary retail distribution channel are up 29% from the same period last year.
"With the implementation of our radio ad campaign beginning in March, as well as key promotional programs, Lifestream is realizing the preliminary impact of increasing consumer awareness for its products," noted Christopher Maus, Lifestream's President and CEO. "When compared to the same period last year, the subset's retail sales activity between mid March through mid May shows a 29% increase verifying that Lifestream's recent advertising and promotional activities are showing significant improvements within targeted retail segments. When compared with the subset's retail sales activity for January through mid March, Lifestream products realized a 19% increase. Generally, sales tend to flatten after the Christmas holiday, but continued retail sales increases reinforce the fact that Lifestream's efforts to raise awareness are having a material impact on retail growth."
وعليه هذا الخبر الحليوة
TC Lifestream Technologies` Advertising and Promotion Programs Kick In; Lifestream Sees Expansion in 2005 as Advertising and Targeted Marketing Increase Sales 29%
July 13, 2004 06:30:00 (ET)
POST FALLS, Idaho, Jul 13, 2004 (BUSINESS WIRE) -- Lifestream Technologies, Inc. (LFTC, Trade), the leading manufacturer of home cholesterol monitors and professional screening devices, today announced that sales within a subset of its primary retail distribution channel are up 29% from the same period last year.
"With the implementation of our radio ad campaign beginning in March, as well as key promotional programs, Lifestream is realizing the preliminary impact of increasing consumer awareness for its products," noted Christopher Maus, Lifestream's President and CEO. "When compared to the same period last year, the subset's retail sales activity between mid March through mid May shows a 29% increase verifying that Lifestream's recent advertising and promotional activities are showing significant improvements within targeted retail segments. When compared with the subset's retail sales activity for January through mid March, Lifestream products realized a 19% increase. Generally, sales tend to flatten after the Christmas holiday, but continued retail sales increases reinforce the fact that Lifestream's efforts to raise awareness are having a material impact on retail growth."
السلام عليكم
الاخ ممدوح واهل الخبرة.
ارجوا المساعدة والتصحيح في تحليل السهم.
اتوقع للسهم اذا كسر 0.0450 سوف يذهب الى 0.0550 ومن ثم الى 6 وشوي واذا كسر هذا المقاومة فالوعد على 0.11 ومن ثم يمكن تحديد السهم اذا كان سوف يواصل الصعود او النزول.
وأذا كسر 0.04 نزولا فسوف يعود الى 3 سنت تقريبا ومن ثم يرتد بالصعود لتحقيق هدفه. والواضح عندي ان هدفه 11 سنت انشاء الله.
وشكراً
الاخ ممدوح واهل الخبرة.
ارجوا المساعدة والتصحيح في تحليل السهم.
اتوقع للسهم اذا كسر 0.0450 سوف يذهب الى 0.0550 ومن ثم الى 6 وشوي واذا كسر هذا المقاومة فالوعد على 0.11 ومن ثم يمكن تحديد السهم اذا كان سوف يواصل الصعود او النزول.
وأذا كسر 0.04 نزولا فسوف يعود الى 3 سنت تقريبا ومن ثم يرتد بالصعود لتحقيق هدفه. والواضح عندي ان هدفه 11 سنت انشاء الله.
وشكراً
Hi again
خبر جيد جدا
Independent Study Shows Lifestream Technologies' Cholesterol Monitor to
Be as Accurate as Physician's Office Test
Monday July 19, 6:30 am ET
Consumers Can Trust Home Test Results
POST FALLS, Idaho--(BUSINESS WIRE)--July 19, 2004--Lifestream Technologies, Inc. (OTCBB:LFTC - News), the leading manufacturer of home cholesterol monitors and professional screening devices, today announced that an independent accuracy and precision study was conducted by Radiant Research, Inc., comparing the Lifestream Cholesterol Monitor against three professional methods: a physician's office lab system, a local independent lab, and the Abell-Kendall method, the US government accuracy and precision standard for all cholesterol test devices.
"It is extremely important that we determine accuracy of at-home testing," stated Dr. Michael Davidson, Medical Director for Radiant Research. "At-home testing provides an opportunity for patients to assume more control of their overall health. If patients can identify the problem early on, they can work with their physician to initiate treatment."
This independent study was conducted at Radiant's Tucson, Arizona, facility under strict scientific controls with trial protocol approved by an Institutional Review Board. The study assessed Lifestream's home cholesterol monitor against an independent lab, a popular physician's office lab system, and the CDC-controlled standard, the Abell-Kendall technique, at a Cholesterol Reference Method Lab. A copy of the study results are available on Lifestream's website at http://www.knowitforlife.com/proresources.asp or by email at gerriv@lifestreamtech.com.
"This study was motivated by recent articles, which implied that results provided by home cholesterol test devices were inaccurate," stated Christopher Maus, Lifestream's President and CEO. "These articles' conclusions, based on non-scientific testing procedures, were assumptive at best and conducted in a casual manner leading the reader to an erroneous conclusion. This journalist approach misleads the public. Although we don't believe any particular media group would intentionally utilize what, in scientific circles, would be considered "junk science," we are trying to reassure the public as to what pure science says about Lifestream's product. The Radiant Research study's conclusions proved that test results obtained with Lifestream's cholesterol monitor were as accurate and precise as the results obtained from a physician's office or an independent lab."
The National Cholesterol Education Program (NCEP) has concluded that home testing can be an important tool in improving adherence to cholesterol programs. Separate studies indicate that as few as 30% of patients remain on statin medication after one year. Home testing has proven to be effective in monitoring blood pressure and glucose; now, it is also effective in cholesterol management programs.
"The results of this preliminary study are clear and unambiguous," stated Jackson Connolly, Lifestream's VP Product Development. "Under strict scientific evaluation protocols and lab practices, the Lifestream Cholesterol Monitor's results prove as accurate as test results received from a physician's office. To further confirm this, a number of other universities are preparing to replicate this study to confirm the results. It is expected that the results of this expanded study will encourage the media to use good journalistic practices relying on scientific literature rather than relying on misleading outcomes from nonscientific methods. We expect the expanded study results to be submitted to important peer review journals."
About Radiant Research
Based near Seattle, Radiant Research (http://www.radiantresearch.com) is a comprehensive clinical research company that provides Phase I-IV clinical drug development services to the biopharmaceutical and medical device industry. Radiant is comprised of more than 50 wholly owned premier clinical research sites nationwide, employing over 1,000 research professionals exclusively focused on providing professional, high-quality comprehensive clinical research services. In the past four years, Radiant has conducted more than 8,400 clinical trials across 18 therapeutic specialties. Radiant's client list includes every major pharmaceutical company and contract research organization and many biotechnology and medical device companies.
About Lifestream Technologies
The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.
The Company's product line aids the health-conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual's efforts to improve compliance. Lifestream's products also integrate a smart card reader further supporting compliance by storing test results on an individual's personal health card for future retrieval, trend analysis and assessment.
Lifestream's monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card® allowing multiple users the ability to store their personal results. Lifestream's products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream's products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.
This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and, in particular, statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second-generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in our most recent Registration Statement on Form SB-2 filed June 10, 2004, and in "Item 1 -- Our Business," "Item 6 -- Our Management's Discussion and Analysis," particularly the discussion under "Risk Factors -- Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003, both filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report, in the aforementioned Form SB-2 and Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.
خبر جيد جدا
Independent Study Shows Lifestream Technologies' Cholesterol Monitor to
Be as Accurate as Physician's Office Test
Monday July 19, 6:30 am ET
Consumers Can Trust Home Test Results
POST FALLS, Idaho--(BUSINESS WIRE)--July 19, 2004--Lifestream Technologies, Inc. (OTCBB:LFTC - News), the leading manufacturer of home cholesterol monitors and professional screening devices, today announced that an independent accuracy and precision study was conducted by Radiant Research, Inc., comparing the Lifestream Cholesterol Monitor against three professional methods: a physician's office lab system, a local independent lab, and the Abell-Kendall method, the US government accuracy and precision standard for all cholesterol test devices.
"It is extremely important that we determine accuracy of at-home testing," stated Dr. Michael Davidson, Medical Director for Radiant Research. "At-home testing provides an opportunity for patients to assume more control of their overall health. If patients can identify the problem early on, they can work with their physician to initiate treatment."
This independent study was conducted at Radiant's Tucson, Arizona, facility under strict scientific controls with trial protocol approved by an Institutional Review Board. The study assessed Lifestream's home cholesterol monitor against an independent lab, a popular physician's office lab system, and the CDC-controlled standard, the Abell-Kendall technique, at a Cholesterol Reference Method Lab. A copy of the study results are available on Lifestream's website at http://www.knowitforlife.com/proresources.asp or by email at gerriv@lifestreamtech.com.
"This study was motivated by recent articles, which implied that results provided by home cholesterol test devices were inaccurate," stated Christopher Maus, Lifestream's President and CEO. "These articles' conclusions, based on non-scientific testing procedures, were assumptive at best and conducted in a casual manner leading the reader to an erroneous conclusion. This journalist approach misleads the public. Although we don't believe any particular media group would intentionally utilize what, in scientific circles, would be considered "junk science," we are trying to reassure the public as to what pure science says about Lifestream's product. The Radiant Research study's conclusions proved that test results obtained with Lifestream's cholesterol monitor were as accurate and precise as the results obtained from a physician's office or an independent lab."
The National Cholesterol Education Program (NCEP) has concluded that home testing can be an important tool in improving adherence to cholesterol programs. Separate studies indicate that as few as 30% of patients remain on statin medication after one year. Home testing has proven to be effective in monitoring blood pressure and glucose; now, it is also effective in cholesterol management programs.
"The results of this preliminary study are clear and unambiguous," stated Jackson Connolly, Lifestream's VP Product Development. "Under strict scientific evaluation protocols and lab practices, the Lifestream Cholesterol Monitor's results prove as accurate as test results received from a physician's office. To further confirm this, a number of other universities are preparing to replicate this study to confirm the results. It is expected that the results of this expanded study will encourage the media to use good journalistic practices relying on scientific literature rather than relying on misleading outcomes from nonscientific methods. We expect the expanded study results to be submitted to important peer review journals."
About Radiant Research
Based near Seattle, Radiant Research (http://www.radiantresearch.com) is a comprehensive clinical research company that provides Phase I-IV clinical drug development services to the biopharmaceutical and medical device industry. Radiant is comprised of more than 50 wholly owned premier clinical research sites nationwide, employing over 1,000 research professionals exclusively focused on providing professional, high-quality comprehensive clinical research services. In the past four years, Radiant has conducted more than 8,400 clinical trials across 18 therapeutic specialties. Radiant's client list includes every major pharmaceutical company and contract research organization and many biotechnology and medical device companies.
About Lifestream Technologies
The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.
The Company's product line aids the health-conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual's efforts to improve compliance. Lifestream's products also integrate a smart card reader further supporting compliance by storing test results on an individual's personal health card for future retrieval, trend analysis and assessment.
Lifestream's monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card® allowing multiple users the ability to store their personal results. Lifestream's products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream's products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.
This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and, in particular, statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second-generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in our most recent Registration Statement on Form SB-2 filed June 10, 2004, and in "Item 1 -- Our Business," "Item 6 -- Our Management's Discussion and Analysis," particularly the discussion under "Risk Factors -- Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003, both filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report, in the aforementioned Form SB-2 and Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.
السلام عليكم
خبر جديد نزل امس قبل السوق. آسف ان لم اضع الخبر.
وهو باختصار برنامج تعليمي عن الجهاز وكيفية استخدامه والعمل به.
Lifestream Announces RxSchool's Launch of National Pharmacy Education Program
Tuesday July 27, 6:30 am ET
Continuing Education Program Focuses on Increasing Patient Adherence Through Home Monitoring
POST FALLS, Idaho--(BUSINESS WIRE)--July 27, 2004--Lifestream Technologies, Inc. (OTCBB:LFTC - News), the leading manufacturer of home cholesterol monitors and professional screening devices, today announced that RxSchool is releasing a new pharmacy continuing education program designed to provide pharmacists with a greater understanding of the role home cholesterol monitoring plays in helping patients manage their cholesterol levels and improve overall patient compliance.
ADVERTISEMENT
Steve Croke, President of RxSchool, stated, "Those patients on cholesterol-lowering drugs rarely stay on them long enough to derive the cardiovascular benefits the therapy can provide. The science is clear that one effective method is for patients to get regular feedback from self monitoring. To educate the pharmacist on this science is key to making a change in adherence. This is one of our best CE programs yet, and we are very excited about being able to provide pharmacists with an opportunity to adopt new tools in their effort to control heart disease."
"With only 30% of patients remaining on statin drugs after the first year, the value of improving patient adherence is undeniable," said Christopher Maus, Lifestream's President and CEO. "Statin drugs, considered by many to be extremely important for Americans' cardiovascular health, is the largest drug sector, exceeding $17 billion a year. Monitoring cholesterol at home is a proven method for enhancing patient adherence. It is very important that pharmacists understand the nature and value of patient self monitoring."
"We are very pleased that RxSchool, one the nation's premier providers for continuing education, has elected to provide this educational campaign for cholesterol management," stated Ed Siemens, Lifestream's COO. "These efforts will provide pharmacists throughout the U.S. with additional knowledge to support their patients in managing cholesterol through home monitoring. The role of home monitoring in the continuum of care is growing in importance. We are pleased that pharmacists, 120,000 strong, will have such a valuable educational resource."
About RxSchool.com
A division of Pharmacy Choice, Inc., RxSchool is an e-learning web portal and software solutions company that provides a comprehensive suite of educational courses and training tools for the health care industry. The RxSchool website is utilized by tens of thousands of pharmacists, pharmacy technicians, physicians and nurses who practice in hospital, retail, managed care, long-term care, private practice and various other health care settings. As a leader in educational solutions for the industry, RxSchool is supported by pharmaceutical industry sponsors and endorsed by industry associations, employers and educational institutions. For more information about RxSchool or Pharmacy Choice, please visit their respective web sites at www.rxschool.com or www.pharmacychoice.com
About Lifestream Technologies
The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.
The Company's product line aids the health-conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual's efforts to improve compliance. Lifestream's products also integrate a smart card reader, further supporting compliance by storing test results on an individual's personal health card for future retrieval, trend analysis and assessment.
Lifestream's monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card®, allowing multiple users the ability to store their personal results. Lifestream's products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream's products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.
This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties and, in particular, statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second-generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in our most recent Registration Statement on Form SB-2 filed June 10, 2004, and in "Item 1 -- Our Business," "Item 6 -- Our Management's Discussion and Analysis," particularly the discussion under "Risk Factors -- Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003, both filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report, in the aforementioned Form SB-2 and Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.
خبر جديد نزل امس قبل السوق. آسف ان لم اضع الخبر.
وهو باختصار برنامج تعليمي عن الجهاز وكيفية استخدامه والعمل به.
Lifestream Announces RxSchool's Launch of National Pharmacy Education Program
Tuesday July 27, 6:30 am ET
Continuing Education Program Focuses on Increasing Patient Adherence Through Home Monitoring
POST FALLS, Idaho--(BUSINESS WIRE)--July 27, 2004--Lifestream Technologies, Inc. (OTCBB:LFTC - News), the leading manufacturer of home cholesterol monitors and professional screening devices, today announced that RxSchool is releasing a new pharmacy continuing education program designed to provide pharmacists with a greater understanding of the role home cholesterol monitoring plays in helping patients manage their cholesterol levels and improve overall patient compliance.
ADVERTISEMENT
Steve Croke, President of RxSchool, stated, "Those patients on cholesterol-lowering drugs rarely stay on them long enough to derive the cardiovascular benefits the therapy can provide. The science is clear that one effective method is for patients to get regular feedback from self monitoring. To educate the pharmacist on this science is key to making a change in adherence. This is one of our best CE programs yet, and we are very excited about being able to provide pharmacists with an opportunity to adopt new tools in their effort to control heart disease."
"With only 30% of patients remaining on statin drugs after the first year, the value of improving patient adherence is undeniable," said Christopher Maus, Lifestream's President and CEO. "Statin drugs, considered by many to be extremely important for Americans' cardiovascular health, is the largest drug sector, exceeding $17 billion a year. Monitoring cholesterol at home is a proven method for enhancing patient adherence. It is very important that pharmacists understand the nature and value of patient self monitoring."
"We are very pleased that RxSchool, one the nation's premier providers for continuing education, has elected to provide this educational campaign for cholesterol management," stated Ed Siemens, Lifestream's COO. "These efforts will provide pharmacists throughout the U.S. with additional knowledge to support their patients in managing cholesterol through home monitoring. The role of home monitoring in the continuum of care is growing in importance. We are pleased that pharmacists, 120,000 strong, will have such a valuable educational resource."
About RxSchool.com
A division of Pharmacy Choice, Inc., RxSchool is an e-learning web portal and software solutions company that provides a comprehensive suite of educational courses and training tools for the health care industry. The RxSchool website is utilized by tens of thousands of pharmacists, pharmacy technicians, physicians and nurses who practice in hospital, retail, managed care, long-term care, private practice and various other health care settings. As a leader in educational solutions for the industry, RxSchool is supported by pharmaceutical industry sponsors and endorsed by industry associations, employers and educational institutions. For more information about RxSchool or Pharmacy Choice, please visit their respective web sites at www.rxschool.com or www.pharmacychoice.com
About Lifestream Technologies
The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.
The Company's product line aids the health-conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual's efforts to improve compliance. Lifestream's products also integrate a smart card reader, further supporting compliance by storing test results on an individual's personal health card for future retrieval, trend analysis and assessment.
Lifestream's monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card®, allowing multiple users the ability to store their personal results. Lifestream's products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream's products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.
This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties and, in particular, statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second-generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in our most recent Registration Statement on Form SB-2 filed June 10, 2004, and in "Item 1 -- Our Business," "Item 6 -- Our Management's Discussion and Analysis," particularly the discussion under "Risk Factors -- Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003, both filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report, in the aforementioned Form SB-2 and Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.
السلام عليكم
ارجوا ابداء الرأي
خبير لصالح الشركة
US Appeals Court Overturns Decision of District Court on HDL Infringement
Monday September 27, 6:30 am ET
Lifestream Technologies Prevails in Its Appeal to the US Court of Appeals for the Federal Circuit
POST FALLS, Idaho--(BUSINESS WIRE)--Sept. 27, 2004--Lifestream Technologies, Inc. (OTCBB:LFTC - News), the leading supplier of cholesterol monitors and professional screening instruments, announced that the U.S. Court of Appeals for the Federal Circuit has reversed an adverse District Court decision against Lifestream and remanded it back to the District Court for further proceedings.
ADVERTISEMENT
Lifestream asserted that a test strip being marketed by Polymer Technology Systems, Inc., which performed measurements of HDL cholesterol, infringed a patent owned by Lifestream. The U.S. District Court for the District of Idaho had ruled that Polymer's test strips did not infringe that patent. The Court of Appeals reversed the District Court's ruling in Lifestream's favor and remanded the matter back to the District Court.
"We are pleased the Court of Appeals overturned the District Court decision. We believe that our HDL patent has significant value," stated Lifestream's President and CEO, Christopher Maus. "In an effort to bring this matter to a conclusion, we have entered into a Letter of Intent with Polymer to come to an agreement to resolve this matter through a licensing arrangement and provide adequate protection of Lifestream's proprietary rights. Ending this costly litigation will allow us to better focus our resources on developing and expanding product awareness."
About Lifestream Technologies
The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.
The Company's product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual's efforts to improve compliance. Lifestream's products also integrate a smart card reader further supporting compliance by storing test results on an individual's personal health card for future retrieval, trend analysis and assessment.
Lifestream's monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card® allowing multiple users the ability to store their personal results. Lifestream's products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream's products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.
Although we believe our claims are well founded in law and fact and that the defendant's counterclaims and defenses are baseless, the outcome of this litigation cannot be predicted with certainty. Should the District Court on retrial not rule in Lifestream's favor, it may be unsuccessful in collecting future royalties from parties utilizing this technology, which may result in the reduction of the net realizable value of the patent.
This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in our most recent Registration Statement on Form SB-2 filed June 10, 2004, and in "Item 1 - Our Business," "Item 6 - Our Management's Discussion and Analysis," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003, both filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report, in the aforementioned Form SB-2 and Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.
--------------------------------------------------------------------------------
Contact:
Lifestream Technologies, Inc.
Gerri Vance, 208-457-9409 ext. 1222 (Investor Relations)
--------------------------------------------------------------------------------
Source: Lifestream Technologies, Inc.
ارجوا ابداء الرأي
خبير لصالح الشركة
US Appeals Court Overturns Decision of District Court on HDL Infringement
Monday September 27, 6:30 am ET
Lifestream Technologies Prevails in Its Appeal to the US Court of Appeals for the Federal Circuit
POST FALLS, Idaho--(BUSINESS WIRE)--Sept. 27, 2004--Lifestream Technologies, Inc. (OTCBB:LFTC - News), the leading supplier of cholesterol monitors and professional screening instruments, announced that the U.S. Court of Appeals for the Federal Circuit has reversed an adverse District Court decision against Lifestream and remanded it back to the District Court for further proceedings.
ADVERTISEMENT
Lifestream asserted that a test strip being marketed by Polymer Technology Systems, Inc., which performed measurements of HDL cholesterol, infringed a patent owned by Lifestream. The U.S. District Court for the District of Idaho had ruled that Polymer's test strips did not infringe that patent. The Court of Appeals reversed the District Court's ruling in Lifestream's favor and remanded the matter back to the District Court.
"We are pleased the Court of Appeals overturned the District Court decision. We believe that our HDL patent has significant value," stated Lifestream's President and CEO, Christopher Maus. "In an effort to bring this matter to a conclusion, we have entered into a Letter of Intent with Polymer to come to an agreement to resolve this matter through a licensing arrangement and provide adequate protection of Lifestream's proprietary rights. Ending this costly litigation will allow us to better focus our resources on developing and expanding product awareness."
About Lifestream Technologies
The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.
The Company's product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual's efforts to improve compliance. Lifestream's products also integrate a smart card reader further supporting compliance by storing test results on an individual's personal health card for future retrieval, trend analysis and assessment.
Lifestream's monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card® allowing multiple users the ability to store their personal results. Lifestream's products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream's products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.
Although we believe our claims are well founded in law and fact and that the defendant's counterclaims and defenses are baseless, the outcome of this litigation cannot be predicted with certainty. Should the District Court on retrial not rule in Lifestream's favor, it may be unsuccessful in collecting future royalties from parties utilizing this technology, which may result in the reduction of the net realizable value of the patent.
This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in our most recent Registration Statement on Form SB-2 filed June 10, 2004, and in "Item 1 - Our Business," "Item 6 - Our Management's Discussion and Analysis," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003, both filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report, in the aforementioned Form SB-2 and Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.
--------------------------------------------------------------------------------
Contact:
Lifestream Technologies, Inc.
Gerri Vance, 208-457-9409 ext. 1222 (Investor Relations)
--------------------------------------------------------------------------------
Source: Lifestream Technologies, Inc.
دورة المؤشرنت للتحليل الفني
50 دينار كويتي